Validation of a Battery of Neuropsychological Tests for Patients With Metastatic Cancer

Abstract

This study aimed to investigate the psychometric properties of Trail Making Test (TMT), Continuous Reaction Time (CRT), Finger Tapping Test (FTT), Digit Span Test (DST), and Mini-Mental State Examination (MMSE) in Brazilian patients with metastatic cancer. Cognitive performance of 178 patients with metastatic cancer and 79 controls was assessed using the TMT, CRT, FTT, DST, and MMSE. Discriminant validity, concurrent validity, and reliability (39 patients were retested after 3-7 days) were investigated. Discriminant validity between groups was observed in TMT, DST, and MMSE. Measures of concurrent validity and cognitive performance were positively correlated with physical performance, education level, and better performance on MMSE. Negative correlations were observed between cognitive function, pain, anxiety, and depression. All tests but FTT demonstrated very good reliability. Thus, all neuropsychological tests but FTT showed psychometric properties that permit their use in clinical and research purposes in patients with metastatic cancer.

Keywords

neoplasms cognition neuropsychological tests psychometrics

Get full access to this article

View all access options for this article.

References

Alcalar

Ozkan

Kucucuk

Aslay

Ozkan

(2012). Association of coping style, cognitive errors and cancer-related variables with depression in women treated for breast cancer. Japanese Journal of Clinical Oncology, 42, 940-947.

American Psychological Association. (2016). Retrieved from http://www.apa.org/search.aspx?query=anxiety. Accessed July 25, 2016.

Arcuri

G. G.

Palladini

Dumas

Lemoignan

Gagnon

(2015). Exploring the measurement properties of the Montreal Cognitive Assessment in a population of people with cancer. Supportive Care in Cancer, 23, 2779-2787.

Arsdale

A. V.

Rosenbaum

Kaur

Pinto

Kuo

D. Y.

Barrera

. . . Nevadunsky

N. S.

(2016). Prevalence and factors associated with cognitive deficit in women with gynecologic malignancies. Gynecologic Oncology, 141, 323-328.

Axelrod

B. N.

Meyers

J. E.

Davis

J. J.

(2014). Finger Tapping Test performance as a measure of performance validity. The Clinical Neuropsychologist, 28, 1-13.

Botega

N. J.

Bio

M. R.

Zomignani

M. A.

Garcia

Jr. Pereira

W. A. B.

(1995). Mood disorders among medical in-patients: A validation study of the hospital anxiety and depression scale (HAD). Revista de Saúde Pública, 29, 355-363.

Brant

J. M.

(2010). Palliative care for adults across the cancer trajectory: From diagnosis to end of life. Seminars in Oncology Nursing, 26, 222-230.

Brucki

S. M. D.

Nitrini

Caramelli

Bertolucci

P. H. F.

Okamoto

I. H.

(2003). Suggestions for utilization of the Mini-Mental State Examination in Brazil. Arquivos de Neuro-Psiquiatria, 61, 777-781.

Bruera

Miller

McCallion

McMillan

Krefting

Hanson

(1992). Cognitive failure in patients with terminal cancer: A prospective study. Journal of Pain and Symptom Management, 7, 192-195.

10.

Centeno

Sanz

Bruera

(2004). Delirium in advanced cancer patients. Palliative Medicine, 18, 184-194.

11.

Christianson

M. K.

Leathem

J. M.

(2004). Development and standardization of the computerized Finger Tapping Test: Comparison with other finger tapping Instruments. New Zealand Journal of Psychology, 33, 44-49.

12.

Cohen

M. Z.

Armstrong

T. S.

(2004). Cognitive dysfunction. In Groenwald

S. G.

Frogge

M. H.

Goodman

Yarbro

C. H.

(Eds.), Cancer symptom management (pp. 151-156). Sudbury, Ontario, Canada: Jones & Bartlett.

13.

Cruzado

J. A.

López-Santiago

Martinez-Marín

José-Moreno

Custodio

A. B.

Feliu

(2014). Longitudinal study of cognitive dysfunctions induced by adjuvant chemotherapy in colon cancer patients. Supportive Care in Cancer, 22, 1815-1823.

14.

Dutta

(2011). Psychostimulants for chemotherapy induced cognitive changes in cancer, Ockham’s razor, anyone? Journal of Cancer Research and Therapeutics, 7, 264-269.

15.

Elsass

(1986). Continuous reaction times in cerebral dysfunction. Acta Neurologica Scandinavica, 73, 1-22.

16.

Folstein

M. F.

Folstein

S. E.

McHugh

P. R.

(1975). Mini-mental state: A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12, 189-198.

17.

Hermelink

Untch

Lux

M. P.

Kreienberg

Beck

Bauerfeind

Münzel

(2007). Cognitive function during neoadjuvant chemotherapy for breast cancer: Results of a prospective, multicenter, longitudinal Study. Cancer, 109, 1905-1913.

18.

Hjermstad

M. J.

Loge

J. H.

Kaasa

(2004). Methods for assessment of cognitive failure and delirium in palliative care patients: Implications for practice and research. Palliative Medicine, 18, 494-506.

19.

Karnofsky

D. A.

Burchenal

J. H.

(1949). Evaluation of chemotherapeutic agents: The clinical evaluation of chemotherapeutic agents in cancer. New York, NY: Columbia University Press.

20.

Kumar

S. P.

(2011). Utilization of brief pain inventory as an assessment tool for pain in patients with cancer: A focused review. Indian Journal of Palliative Care, 17, 108-115.

21.

Kurita

G. P.

de Mattos Pimenta

C. A.

(2008). Cognitive impairment in cancer pain patients receiving opioids: A pilot study. Cancer Nursing, 31, 49-57.

22.

Kurita

G. P.

de Mattos Pimenta

C. A.

Braga

P. E.

Frich

Jørgensen

M. M.

Nielsen

P. R.

. . . Sjøgren

(2008a). Cognitive function in patients with chronic pain treated with opioids: Characteristics and associated factors. Acta Anaesthesiologica Scandinavica, 56, 1257-1268.

23.

Kurita

G. P.

de Mattos Pimenta

C. A.

Oliveira Júnior

J. O.

Caponeiro

(2008b). Alteration in attention and cancer pain treatment. Revista da Escola de Enfermagem da USP, 42, 143-151.

24.

Kurita

G. P.

Lundorff

de Mattos Pimenta

C. A.

Sjøgren

(2009). The cognitive effects of opioids in cancer: A systematic review. Supportive Care in Cancer, 17, 11-21.

25.

Kurita

G. P.

Sjøgren

Ekholm

Kaasa

Loge

J. H.

Poviloniene

Klepstad

(2011). Prevalence and predictors of cognitive dysfunction in opioid-treated patients with cancer: A multinational study. Journal of Clinical Oncology, 29, 1297-1303.

26.

Landis

Koch

G. G.

(1977). The measurement of observer agreement for categorical data. Biometrics, 33, 159-174.

27.

Lange

Rigal

Clarisse

Giffard

Sevin

Barillet

. . . Joly

(2014). Cognitive dysfunctions in elderly cancer patients: A new challenge for oncologists. Cancer Treatment Reviews, 40, 810-817.

28.

Lezak

Howieson

D. B.

Loring

D. W.

(2004). Neuropsychological assessment. New York, NY: Oxford University Press.

29.

Llinas-Reglà

Vilalta-Franch

López-Pousa

Calvó-Perxas

Torrents Rodas

Garre-Olmo

(2015). The Trail Making Test: Association with other neuropsychological measures and normative values for adults aged 55 years and older from a Spanish-speaking population-based sample. Assessment, 24, 183-196.

30.

Loring

D. W.

(1999). INS dictionary of neuropsychology. New York, NY: Oxford University Press.

31.

Lourenço

R. A.

Veras

R. P.

(2008). Mini-Mental State Examination: Psychometric characteristics in elderly outpatients. Revista de Saúde Pública, 40, 712-719.

32.

Mitrushina

M. N.

Boone

K. B.

D’Elia

L. F.

(1999). Handbook of normative data for neuropsychological assessment. New York, NY: Oxford University Press.

33.

Mystakidou

Tsilika

Parpa

Galanos

Vlahos

(2007a). Brief cognitive assessment of cancer patients: Evaluation of the Mini-Mental State Examination (MMSE) psychometric properties. Psycho-Oncology, 16, 352-357.

34.

Mystakidou

Tsilika

Parpa

Pathiaki

Patiraki

Galanos

Vlahos

(2007b). Exploring the relationships between depression, hopelessness, cognitive status, pain, and spirituality in patients with advanced cancer. Archives of Psychiatric Nursing, 21, 150-161.

35.

Nitrini

(2004). Neurologic Semiology. In Nitrini

Bacheschi

L. A.

(Eds.), The neurology every doctor should know (pp. 55-83). Sao Paulo, SP: Atheneu.

36.

Nitrini

Levèfre

B. H.

Mathias

S. C.

Caramelli

Carrilho

P. E. M.

Sauaia

. . . Scaff

(1994). Brief and easy-to-administer neuropsychological tests in the diagnosis of dementia. Arquivos de Neuro-Psiquiatria, 52, 457-465.

37.

Reitan

R. M.

(1958). Validity of the Trail Making Test as an indicator of organic brain damage. Perceptual and Motor Skills, 8, 271-276.

38.

Santos

de Mattos Pimenta

C. A.

Kurita

G. P.

Braga

Sjøgren

(2014). Validation of the Trail Making Test B for the cognitive assessment of patients with cancer in palliative care. Open Journal of Statistics, 4, 435-445.

39.

Scheibel

R. S.

Valentine

A. D.

O’Brien

(2004). Cognitive dysfunction and depression during treatment with interferon-alpha and chemotherapy. The Journal of Neuropsychiatry and Clinical Neurosciences, 16, 185-191.

40.

Sjøgren

(1997). Psychomotor and cognitive functioning in cancer patients. Acta Anaesthesiologica Scandinavica, 41, 159-161.

41.

Sjøgren

Olsen

A. K.

Thomsen

A. B.

Dalberg

(2000). Neuropsychological performance in cancer patients: The role of oral opioids, pain and performance status. Pain, 86, 237-245.

42.

Spreen

Strauss

(1998). A compendium of neuropsychological tests: Administration, norms and commentary. New York, NY: Oxford University Press.

43.

Taillibert

Voillery

Bernard-Marty

(2007). Chemobrain: Is systemic chemotherapy neurotoxic? Current Opinion in Oncology, 19, 623-627.

44.

Tchen

Juffs

H. G.

Downie

F. P.

Q. L.

Chemerynsky

. . . Tannock

I. F.

(2003). Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. Journal of Clinical Oncology, 21, 4175-4183.

45.

Tombaugh

T. N.

McIntyre

N. J.

(1992). The Mini-Mental State Examination: A comprehensive review. Journal of the American Geriatrics Society, 40, 922-935.

46.

Vearncombe

K. J.

Rolfe

Wright

Paxana

N. A.

Andrew

Beadle

(2009). Predictors of cognitive decline after chemotherapy in breast cancer patients. Journal of the International Neuropsychological Society, 15, 951-962.